A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

August 20, 2028

Study Completion Date

February 20, 2035

Conditions
Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions
DRUG

Linvoseltamab

anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

Trial Locations (18)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

31008

RECRUITING

Clinica Universidad de Navarra - Pamplona, Pamplona

33203

RECRUITING

Hospital de Cabuenes, Gijón

37203

RECRUITING

SCRI Oncology Partners, Nashville

43210

RECRUITING

Ohio State University, Columbus

46026

RECRUITING

University Hospital La Fe, Valencia

48201

RECRUITING

Karmanos Cancer Institute, Detroit

77030

RECRUITING

MD Anderson Cancer Center, Houston

80218

RECRUITING

Colorado Blood Cancer Institute/SCRI, Denver

91010

RECRUITING

City of Hope, Duarte

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

065791

RECRUITING

Seoul St. Mary's Hospital - The Catholic University of Korea, Seoul

07120

RECRUITING

Hospital Universitari Son Espases, Palma

08036

RECRUITING

Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona

NW1 2PG

RECRUITING

University College London Hospitals, London

M20 4BQ

RECRUITING

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY